Additionally, ctDNA sequencing in colorectal and breast cancer patients can allow for the detection of chromosome copy number and structural alterations that are therapeutically relevant (161, 162), or HER2 amplifications in patients with gastric cancer treated with trastuzumab (163). Here, ERBB2 is linked to breast cancer.